Tonix Pharmaceuticals, a leading company in vaccine development, has announced that their COVID-19 vaccine, TNX-1800, has been selected for testing in Project Next Gen. This initiative is managed by the White House and the Department of Health and Human Services, NIH, and NIAID.

TNX-1800 uses a live virus platform that offers a unique way of stimulating the immune system. This method provides longer-lasting and potentially transmission-blocking immunity compared to mRNA vaccines. The selection of TNX-1800 for this program is a result of Tonix Pharmaceuticals’ almost ten years of dedication to vaccine development. Furthermore, the technology platform can be adapted to protect against other infectious diseases such as monkeypox, smallpox, and tuberculosis.

This choice of TNX-1800 represents the importance of vaccine platforms in addressing various infectious threats. Tonix’s approach offers the promise of more durable immunity and potential transmission prevention, potentially revolutionizing our approach to infectious disease control. The platform’s adaptability makes it a valuable tool for future vaccine strategies, making it a versatile solution for future pandemics.

For more information about Tonix Pharmaceuticals and TNX-1800 please contact Proactive Studio at +1 347-449-0879 or email them at na-editorial@proactiveinvestors.com